The global Keytruda Market was valued at USD 31.4 billion in 2025 and is projected to grow from USD 32.7 billion in 2026 to USD 25.0 billion by 2033, registering a CAGR of -3.8% from 2026 to 2033. While Keytruda (pembrolizumab) remains one of the most successful immunotherapy drugs globally, the market is expected to face headwinds over the forecast period due to patent expiration,...

The North America Colorectal Cancer Market holds a dominant position globally due to the region's well-established healthcare systems, high healthcare expenditure, and growing focus on cancer prevention and management. Countries such as the United States and Canada are witnessing increased adoption of advanced diagnostic techniques and innovative therapeutic approaches, including immunotherapy...

The global healthcare and oncology sectors are witnessing rapid advancements in cancer therapeutics, particularly in the treatment of rare and aggressive blood cancers such as mantle cell lymphoma (MCL). Increasing awareness regarding early diagnosis, advancements in targeted therapies, and growing investments in oncology research are significantly contributing to industry expansion. The rising...

The US Immunotherapy Drugs Market represents the largest share of the global market, driven by a high prevalence of cancer and autoimmune disorders, substantial healthcare spending, and strong investments in biopharmaceutical research and development. The country is home to many leading pharmaceutical and biotechnology companies actively developing innovative immunotherapy treatments, including...